Efficient and versatile manipulation of the peripheral CD4+ T‐cell compartment by antigen targeting to DNGR‐1/CLEC9A
Open Access
- 29 April 2010
- journal article
- highlights
- Published by Wiley in European Journal of Immunology
- Vol. 40 (5) , 1255-1265
- https://doi.org/10.1002/eji.201040419
Abstract
DC NK lectin group receptor‐1 (DNGR‐1, also known as CLEC9A) is a C‐type lectin receptor expressed by mouse CD8α+ DC and by their putative equivalents in human. DNGR‐1 senses necrosis and regulates CD8+ T‐cell cross‐priming to dead‐cell‐associated antigens. In addition, DNGR‐1 is a target for selective in vivo delivery of antigens to DC and the induction of CD8+ T‐cell and Ab responses. In this study, we evaluated whether DNGR‐1 targeting can be additionally used to manipulate antigen‐specific CD4+ T lymphocytes. Injection of small amounts of antigen‐coupled anti‐DNGR‐1 mAb into mice promoted MHC class II antigen presentation selectively by CD8α+ DC. In the steady state, this was sufficient to induce proliferation of antigen‐specific naïve CD4+ T cells and to drive their differentiation into Foxp3+ regulatory lymphocytes. Co‐administration of adjuvants prevented this induction of tolerance and promoted immunity. Notably, distinct adjuvants allowed qualitative modulation of CD4+ T‐cell behavior: poly I:C induced a strong IL‐12‐independent Th1 response, whereas curdlan led to the priming of Th17 cells. Thus, antigen targeting to DNGR‐1 is a versatile approach for inducing functionally distinct CD4+ T‐cell responses. Given the restricted pattern of expression of DNGR‐1 across species, this strategy could prove useful for developing immunotherapy protocols in humans.Keywords
This publication has 41 references indexed in Scilit:
- Enhancing immune responses by targeting antigen to DCEuropean Journal of Immunology, 2009
- Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectinJournal of Clinical Investigation, 2008
- Dendritic-cell immunotherapy: from ex vivo loading to in vivo targetingNature Reviews Immunology, 2007
- Taking dendritic cells into medicineNature, 2007
- Dendritic cells: versatile controllers of the immune systemNature Medicine, 2007
- A subset of dendritic cells induces CD4+ T cells to produce IFN-γ by an IL-12–independent but CD70-dependent mechanism in vivoThe Journal of Experimental Medicine, 2007
- Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responsesThe Journal of Experimental Medicine, 2006
- In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell VaccinationThe Journal of Experimental Medicine, 2004
- Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell ToleranceThe Journal of Experimental Medicine, 2002
- Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in VivoThe Journal of Experimental Medicine, 2001